News
May 18, 2011 - Jasbir Sra, M.D., and Tanvir Bajwa, M.D., are the first in Wisconsin to implant a new device in a patient’s heart that may reduce strokes in individuals suffering from atrial fibrillation, a common heart arrhythmia. This minimally invasive procedure was part of a clinical trial taking place at Aurora St. Luke’s Medical Center.
May 18, 2011
Technology
May 18, 2011 - Arstasis is pleased to announce the U.S. launch of its latest commercial product - the Axera Access Device. The Axera Device enhances insertability into the femoral artery and overall procedural usage while continuing to deliver the clinical benefits of the implant-free arstaotomy procedure.
May 18, 2011
This podcast explains how syngo Dynamics can be used to integrate cardiac imaging picture archiving and communication ...
May 16, 2011Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024News
May 16, 2011 - Cordis announces the launch in Europe of Radial Solutions, a complete portfolio for transradial interventions. New to the portfolio is the Cordis Radialsource Transradial Access Kit. Radialsource Transradial Sheaths are designed to provide physicians with atraumatic and smooth access to the radial artery during diagnostic and interventional procedures.
May 16, 2011
News
May 16, 2011— GE Healthcare today received the Price Performance Value Leadership Award in PET (Positron Emission Tomography) for North America 2011 from global research organization Frost & Sullivan.
May 16, 2011
News
May 16, 2011 - The German Supreme Court (BGH) declared a structural heart occluder patent case to be invalid. In the ruling by the BGH, the court does not see any basis for AGA/St. Jude's claim that the Occlutech atrial septal defects and patent foramen ovale (ASD and PFO) occluders violate any patent brought forward in the litigation and declares earlier German ruling to the contrary invalid.
May 16, 2011Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News
May 16, 2011 – In a coronary stent patent lawsuit, a jury said Cordis owes Boston Scientific approximately $19.5 million.
May 16, 2011
News
May 16, 2011 - The first patient was recently enrolled in the INOVATE-HF (INcrease Of VAgal TonE in Heart Failure) clinical study to determine the safety and efficacy of BioControl Medical’s CardioFit system. The implantable electrical stimulation device is designed to improve heart function in patients with congestive heart failure (HF). The first patient was enrolled at Northwest Texas Heart Hospital, Amarillo, Texas, by study investigator Suresh Neelagaru, M.D.
May 16, 2011
Case Study
Michael Ringold, M.D., an interventional radiologist at St. Luke’s Hospital in Bethlehem, Pa., shared a case in which he used GE Healthcare’s Innova 4100 IQ interventional imaging system to perform dual embolizations on a 56-year-old man with liver cancer.
May 11, 2011Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023News
May 11, 2011 - Micell Technologies announced that positive preclinical data will be presented at the EuroPCR conference regarding the MiStent Drug-Eluting Coronary Stent System (MiStent DES), an ultra-thin, advanced alloy drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. The data will be presented in Paris, France on May 18, 2011 in a presentation titled "MiStent DES: A Novel Third Generation DES with a Fully-absorbable Coating and Enhanced Drug Delivery Capabilities."
May 11, 2011News
Virginia, Minn. – Every day, Jack Luzovich steps on a special scale that helps keep him in his northern Minnesota home, rather than the hospital. At age 61, he is fighting the debilitating symptoms of congestive heart failure. Last summer, his health hit a low point. “I was retaining fluid and my weight was going up and down,” he remembers. “I couldn’t walk more than 10 to 15 feet. I was on oxygen, jaundiced and had almost no kidney function.” That’s when Jack received a telemonitoring scale from the Essentia Health Heart Failure Program (formerly St. Mary’s Duluth Clinic Heart Failure Program). The device records his weight and asks him questions about his health. It transmits that vital information to a cardiac nurse, who can make changes to his medications and track his condition on a daily basis.
May 11, 2011
Case Study
Aortic dissection is rare, but when it occurs, a patient’s prognosis can be poor, even with timely medical diagnosis and treatment. It is the most frequently diagnosed lethal condition of the aorta. In the past, a type A dissection had been treated with surgery and a type B dissection with drugs to lower blood pressure and heart rate. Another option, thoracic endovascular aortic repair (TEVAR), where a stent-graft is placed inside the aorta, was introduced in 1999. This procedure restores the normal aortic anatomy to prevent aortic expansion or rupture. A study in the April issue of the Journal of Endovascular Therapy evaluates the performance of a specific stent-graft, the Relay thoracic stent-graft.
May 11, 2011Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
Feature
May 11, 2011 – Terumo entered into a purchase agreement to acquire Harvest Technologies Corp, which is working to commercialize the world's first point-of-care stem cell therapy.
May 11, 2011
News
May 11, 2011 -The American Society of Echocardiography (ASE) will host its 22nd Annual Scientific Sessions: The Patient the Image: The Role of Cardiovascular Ultrasound in Clinical Decision Making (ASE 2011), June 11-14 at the Palais des Congres de Montreal in Montreal, Quebec, Canada.
May 11, 2011News
May 10, 2011 – The Impella percutaneously deployed ventricular assist device showed an overall average hospital charge savings when compared to the standard-of-care intra-aortic balloon pump (IABP). The economic analyses is based on data from the PROTECT II study, which compares Impella to IABP hemodynamic support.
May 11, 2011© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now